Journal of neurology · 2025
Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ju Yalin, Geng Chang, Guan Hongzhi
Аннотация
OBJECTIVE: To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).
METHODS: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included. Methodological quality was assessed independently by two authors. Data on clinical features, neuroimaging patterns and outcomes were analyzed.
RESULTS: In total, 77 cases from 21 studies were included. Most patients had fever and seizures. Respiratory viruses were common precipitating infection. All patients had bilateral thalamic lesions, and brainstem lesions were more frequently observed in the tocilizumab group (88.0% vs 64.0%, p = 0.04). The length of hospital stay was significantly longer in the tocilizumab group both before (p = 0.01) and after propensity score matching (PSM) (p = 0.02), while the mortality rate was significantly lower in tocilizumab compared with non-tocilizumab group (8.0% vs 33.3%, p = 0.02). Initiation of tocilizumab within 24 h was related to a good outcome both before (p < 0.01) and after PSM (p < 0.01). In multivariate regression analysis, elder age and < 24 h immunotherapy were independently related with good outcome (age: aOR = 1.35; 95% CI 1.06-1.74, p = 0.02; < 24 h immunotherapy: aOR = 8.60; 95% CI 1.08-68.63, p = 0.04). Brainstem lesions was an independent risk factor of poor outcome (aOR = 0.03; 95% CI 0.003-0.29, p < 0.01). Tocilizumab use was independently associated with reduced mortality (aOR = 7.95, 95%CI 1.47-43.03, p = 0.02). No adverse effects were reported.
CONCLUSION: This review suggests that timely initiation of tocilizumab therapy within 24 h is safe, and may be an effective treatment in ANE, providing a strong rationale for a clinical trial.
METHODS: PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included. Methodological quality was assessed independently by two authors. Data on clinical features, neuroimaging patterns and outcomes were analyzed.
RESULTS: In total, 77 cases from 21 studies were included. Most patients had fever and seizures. Respiratory viruses were common precipitating infection. All patients had bilateral thalamic lesions, and brainstem lesions were more frequently observed in the tocilizumab group (88.0% vs 64.0%, p = 0.04). The length of hospital stay was significantly longer in the tocilizumab group both before (p = 0.01) and after propensity score matching (PSM) (p = 0.02), while the mortality rate was significantly lower in tocilizumab compared with non-tocilizumab group (8.0% vs 33.3%, p = 0.02). Initiation of tocilizumab within 24 h was related to a good outcome both before (p < 0.01) and after PSM (p < 0.01). In multivariate regression analysis, elder age and < 24 h immunotherapy were independently related with good outcome (age: aOR = 1.35; 95% CI 1.06-1.74, p = 0.02; < 24 h immunotherapy: aOR = 8.60; 95% CI 1.08-68.63, p = 0.04). Brainstem lesions was an independent risk factor of poor outcome (aOR = 0.03; 95% CI 0.003-0.29, p < 0.01). Tocilizumab use was independently associated with reduced mortality (aOR = 7.95, 95%CI 1.47-43.03, p = 0.02). No adverse effects were reported.
CONCLUSION: This review suggests that timely initiation of tocilizumab therapy within 24 h is safe, and may be an effective treatment in ANE, providing a strong rationale for a clinical trial.